Thanks to the efforts and dedication of our co-founder Dr. Ramy Saleh, McGill enrolled the first patient into the Calgary’s Cart T cell trial for advanced alveolar soft-part sarcoma.
SaRC-Q Co-founder Dr. Ramy Saleh Leads Milestone in Sarcoma Research
In a significant milestone for sarcoma research, SaRC-Q co-founder Dr. Ramy Saleh has played a pivotal role in enrolling the first patient into the Calgary’s CART T-cell trial for advanced alveolar soft-part sarcoma (ASPS).
A Step Forward in Advanced Alveolar Soft-Part Sarcoma Treatment
Dr. Ramy Saleh’s dedication and tireless efforts have led to McGill’s enrollment in the cutting-edge CART T-cell trial, offering hope to those facing advanced alveolar soft-part sarcoma. CART T-cell therapy, a revolutionary immunotherapy approach, involves harnessing the patient’s immune system to target and combat cancer cells.
A Testament to SaRC-Q’s Commitment
This achievement underscores SaRC-Q’s commitment to pushing the boundaries of sarcoma research. Dr. Saleh’s leadership exemplifies the collaborative spirit and unwavering dedication of our team in advancing innovative treatments for rare and challenging forms of sarcoma.
A Brighter Future in Sarcoma Care
SaRC-Q congratulates Dr. Ramy Saleh and the entire team at McGill for this groundbreaking accomplishment. Enrolling the first patient into the Calgary’s CART T-cell trial is a significant step forward in our collective mission to transform the future of sarcoma care.
Stay tuned for further updates as we continue to strive for advancements that make a meaningful impact on the lives of sarcoma patients.